Patients often regain some weight after stopping a GLP-1, but your clinician will help you set realistic expectations and find a plan that works for you
Retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and no marketing authorisation application has been approved as of the date of publication of this article
37 Disruption of hormone production and secretion from the pancreatic islets, as well as impaired action on target tissues, results in impaired metabolic homeostasis and diseases such as diabetes
What Clients Are Telling Me about their experience with GLP-1s Client responses to GLP-1s vary widely: Some experience little to no appetite or weight changepossibly requiring dose adjustments
Even for those who qualify, getting a consistent supply can be a challenge
Tirzepatide is more effective for blood sugar control, and retatrutide was most effective in managing diabetic kidney disease and body weight